The global competent cells market is expected to reach USD 2.1 Billion by the end of 2022, registering double-digit growth at 11.1% CAGR during the forecast period (2022 to 2032). Sales in the market are expected to reach a valuation of ~USD 5.9 Billion by 2032. In terms of product type, chemically competent cells led the market with a share of about 67.8% in 2021.
Competent cells are bacterial cells that can utilize foreign DNA from their surroundings through a process known as transformation. Griffith described it initially in Streptococcus pneumoniae. If the cell walls of E. coli are changed, the cells tend to absorb the DNA. Calcium chloride and temperature shock therapy can make the cells competent. Rapidly growing cells can be rendered more competent than cells at other phases of development.
| Attributes | Key Insights |
|---|---|
| Competent Cells Market Value 2021 | USD 1.9 Billion |
| Estimated Market Size 2022 | USD 2.1 Billion |
| Projected Market Value 2032 | USD 5.9 Billion |
| CAGR 2022 to 2032 | 11.1% |
| Market Share of Top 5 Countries | 57.4% |
Exclusive Offer: 30% Off on Regional Reports
Get a free sample report and customize your regions for a 30% discount on your regional report!
Cloning is expected to expand significantly in the application area due to the growing demand for molecularly cloned items. The cloning sector has benefited from COVID-19 as a result of corporations investing more money in research and development. Furthermore, it is anticipated that the segment would develop faster because of increased cloning research and financial assistance from a number of organizations.
Techniques for cell engineering, such as somatic cell nuclear transfer (SCNT), have demonstrated a variety of uses, including the creation of transgenic animals, the preservation of endangered species, and therapeutic cloning. Since competent cells may be employed in therapeutic cloning research, these fields are anticipated to experience renewed attention, which will lead to an increase in demand for these cells.
Due to rising Research and Development expenditures and the commercialization of proteomics and genomics-based goods, the biotechnology sector is also anticipated to see a significant growth rate. The need for cutting-edge product advancements in the treatment of different ailments is also anticipated to support the segment's expansion. Additionally, it is projected that increased investment in research into DNA cloning methods at academic research facilities and the usage of these products in therapies will accelerate market growth in the near future.
During the projected period, it is predicted that the Asia-Pacific market would account for a large portion of the worldwide competent cells market. Extensive research on DNA cloning methods in the area and the existence of significant market participants are credited with the expansion.
For instance, Takara Bio Inc. stated in January 2021 that its new facility, the Center for Gene and Cell Processing II, for manufacturing and research purposes, had been completed in Shiga, Japan.
China is expected to develop at a profitable CAGR of 10.1% throughout the projected period and will hold a market share of around 54.2% in East Asia in 2021. The competent cells market will grow as research funding and activity increase.
For instance, the State Key Laboratory of Microbial Application, the Natural Science Foundation of China, and SDU's Qilu Youth Scholar Start-up Funding all provided funding for a research study on Escherichia coli BW25113 competent cells made using a straightforward chemical method that has unparalleled transformation and cloning efficiencies in 2022.
Another regional company, HiMedia Solutions, is situated in India and produces a wide range of goods for the market for competent cells. The HiPurA BL21(DE3) Competent Cells, Bacterial Transformation Kit, HiPurA XL1-Blue Competent Cells, and HiPurA Competent Cells are its four main items for this market. The business is India's top producer of trustworthy cells. Its goods made cloning experiments simpler, such as the HiPurA Competent Cells, which were the first competent DH5a cells marketed on the Indian market. The existence of such businesses is probably going to benefit market growth.
Competent cells are bacterial cells, which can utilize foreign DNA from their surroundings through a process known as transformation. Griffith described it initially in Streptococcus pneumoniae. If the cell walls of E.coli are changed, the cells have a greater tendency to absorb the DNA.
Calcium chloride and temperature shock therapy can make the cells competent. Rapidly growing cells can be rendered more competent than cells at other phases of development. Following transformation, the cells may express the acquired genetic information.
As per Future Market Insights (FMI), the competent cells market was approximately 12.8% of the overall USD 14.5 Billion global cell expansion market in 2021. Overall sales of competent cells expanded at a CAGR of 9.9% from 2017 to 2021, on the back of the rising expansion of the healthcare industry.
Increasing adoption of molecular cloned products, recombinant proteins, advancement in molecular cloning research and development with the emergence of new technologies, and numerous government initiatives and government grants available for life science research are the key factors driving industry growth during the forecast period.
Gene therapy can potentially treat a wide range of ailments. The increasing prevalence of cancer, cardiovascular diseases, cystic fibrosis, blood disorders, and immunocompromised cases is rising, which will boost the market in the forecast period. Gene therapy attempts to cure an ailment or enhance your body's capacity to fight disease by replacing a malfunctioning gene or introducing a new gene.
According to World Health Organization (WHO) 2022, cancer is the largest cause of mortality around the globe, accounting for over 10 million deaths in 2020, or roughly one in every six. Colon, lung, breast, rectum, and prostate cancers are the most prevalent. Tobacco use, obesity, alcohol consumption, a lack of consumption of fruits and vegetables, and an insufficient level of physical activity account for almost one-third of cancer fatalities.
In addition, cystic fibrosis is a widespread hereditary condition throughout the white population in the USA. The condition affects one in every 2,500 to 3,500 white babies. Cystic fibrosis affects around one in every 17,000 African Americans and 31,000 Asian Americans, as stated by MedlinePlus in 2021. These conditions require gene therapy, which will positively impact the competent cells market. Backed by these aforementioned factors, the global competent cells market is expected to grow at a CAGR of 11.1% during the forecast period.
Favorable Government Initiatives for Gene Therapy Products to Push the Sales
Growth in the market is predicted to surge on the back of favourable initiatives by governments in emerging countries, increasing FDA approval for gene therapy products, and advancements in research and developmental activities. These factors will boost the demand for better technologies, creating a conducive environment in the competent cells market.
Recombinant DNA technology is one of the most commonly used techniques in introducing a specific gene or a healthy gene into a vector. These vectors can be plasmodial, viral, or nanostructured; the latter is the most commonly used because of its efficacy in colonizing cells and incorporating their genetic material.
Recent advances in recombinant DNA synthesis have enabled the effective production of recombinant proteins at industrial sizes with higher yields and lower production costs. This has enabled the development of new treatments, vaccines, and diagnostic reagents.
Certain nutrients are allowed to clone human genes, which reduces the likelihood of unfavourable immune system reactions in patients, allows for the creation of highly specialized, functional, and active proteins, increases productivity and cost-effectiveness, and reduces the possibility of unknown pathogen transmission from animals or humans.
Check Free Sample Report & Save 40%!
Select your niche segments and personalize your insights for smart savings. Cut costs now!
The rising costs of research and developmental activities and stringent regulations in the field might hamper the growth in the forecast period. Competent cells are utilized in molecular cloning procedures, protein expression, and various plasmid DNA-based applications.
However, depending on the transformation method, for instance, developing the E. coli competent cells can be time-consuming, needing exceptionally pure water, high-grade reagents, specified autoclaved glassware, and or even specialized equipment (electroporators).
Numerous protocols available describe the technique and buffers needed to produce competent cells. There are even kits available that include pre-made buffers to expedite this process. Furthermore, it is more expensive to use electroporation.
A specialized apparatus is required to implement the charge, in addition to cuvettes to transport the charge to the cell solution. Excess salt in the cuvette can cause electroporation to fail and result in the loss of valuable samples. The most widely mentioned disadvantage of chemical transformation is its reduced efficiency.
Growing Investment in Gene Cell Therapy Products to Boost the Demand
The USA dominated the North American competent cells market and accounted for nearly 84.8% in 2021. Demand in the market is anticipated to surge on the back of rising investment in gene therapy products. Further, increasing research and development by government bodies, grants, and clinical trials for disease treatment and others, will improve the growth of the competent cells market.
China Competent Cells Market to Benefit from Rising Research & Development for Cloning Efficiency
China held approximately 54.2% share in the East Asia competent cells market in 2021. Demand for competent cells in China will rise at a CAGR of 10.1% during the forecast period. Increasing research activities and grants will propel the competent cells market.
For instance, the Natural Science Foundation of China, the funding by the State Key Laboratory of Microbial Application, and the Qilu Youth Scholar Start-up Funding of SDU, funded a research study on Escherichia coli BW25113 competent cells prepared using a simple chemical method having unmatched transformation and cloning efficiencies, in 2022.
Introduction of Different Strains for Gene Transformation to Propel Sales
As per FMI, the overall sales in the German competent cells market are projected to expand at 9.3% CAGR in the Europe competent cells market during the forecast period. Increasing production activities by manufacturers to develop different types of strains, which allows easy gene transformation, will propel the market. For instance, New England Biolabs GmbH has products specific to cloning & subcloning and strains for protein expression, with each type having quality specifications.
Nearly 7 out of 10 Sales to be Contributed by Chemically Competent Cells
Chemically competent cells are expected to present high growth at a CAGR of 15.3% between 2022 and 2032, with a share of about 67.8% in 2021. Cloning, DNA sequencing, and the creation of DNA libraries are just a few of the many molecular biology techniques that frequently include transformation. Competent cells must be used to perform the transformation. Chemically competent cells hold a bigger market share because chemical transformation is quicker and less error-prone than electroporation.
Cloning Segment to Account for Around 3/5th of Competent Cells Sales
In terms of application, the cloning segment held a revenue share of 57.8% in 2021 and is expected to display steady growth over the forecast period. Competent cells are frequently employed in molecular cloning to increase and preserve cloned DNA in plasmids because they are engineered to absorb foreign DNA from the environment more efficiently. With growing investments in cell and gene therapy, the cloning segment holds a higher market share in terms of application within the overall competent cells market, globally.
Based on end users, the academic research institutes held the highest market share value of 51.2% in 2021. Increasing research and development activities in life sciences are propelling sales of the overall competent cells market.
With several competitors in the competent cells market, the overall market is fragmented. To expand their customer base, leading companies are implementing methods such as mergers and acquisitions, partnerships and collaborations, and new product launches.
For instance:
| Attribute | Details |
|---|---|
| Estimated Market Size 2022 | USD 2.1 Billion |
| Projected Market Value 2032 | USD 5.9 Billion |
| CAGR 2022 to 2032 | 11.1% |
| Forecast Period | 2017 to 2021 |
| Historical Data Available for | 2022 to 2032 |
| Market Analysis | USD Million for Value |
| Key Regions Covered | North America; Latin America; Europe; South Asia; East Asia; Oceania; and Middle East & Africa |
| Key Countries Covered | USA, Canada, Brazil, Mexico, Argentina, UK, Germany, Italy, Russia, Spain, France, BENELUX, India, Thailand, Indonesia, Malaysia, Japan, China, South Korea, Australia, New Zealand, Turkey, GCC Countries, South Africa, and North Africa |
| Key Market Segments Covered | Product, Application, End User, and Region |
| Key Companies Profiled | Agilent Technologies Inc.; Genescript Biotech Corporation; Bio-Rad Laboratories Inc; Merck & Co Inc; OriGene Technologies, Inc; New England Biolabs Inc; Illumina, Inc.; Thermo Fisher Scientific, Inc.,; QIAGEN N.V.,; Zymo Research Corporation; Promega Corporation; HiMedia Laboratories; Avantor, Inc.; Scarab Genomics, LLC; Lucigen; bluebird bio, Inc.; Tonbo Biosciences; TransGen Biotech; Codex DNA, Inc. |
The global competent cells market is worth USD 1.9 Billion in 2021 and is set to expand by 2.9X over the next ten years.
The competent cells market is expected to reach USD 5.9 Billion by the end of 2032, with sales revenue expected to register an 11.1% CAGR.
The growing prevalence of genetic disorders and increasing research and developments are some of the key trends in this market.
The USA, India, China, Germany, and Japan are expected to drive demand for the competent cells industry.
North America is expected to lead the growth in the competent cells market, with the USA accounting for about 84.8% of the share in 2021.
Demand for competent cells in Europe is expected to register a growth of 10.9% over the next ten years.
Demand for competent cells in Latin America is expected to register a growth at 10.6% CAGR over the next ten years
Demand for competent cells in MEA is expected to register a growth of 8.7% over the next ten years
China, the USA, and Germany are the key producers of competent cells.
| Estimated Size, 2024 | USD 6,485.3 million |
|---|---|
| Projected Size, 2034 | USD 14,528.6 million |
| Value-based CAGR (2024 to 2034) | 11.2% |
| Estimated Market Size (2024E) | USD 688.1 million |
|---|---|
| Projected Market Value (2034F) | USD 3,713.1 million |
| Value-based CAGR (2024 to 2034) | 18.4% |
| Market Expected Value (2023) | USD 779.4 million |
|---|---|
| Market Forecast Value (2033) | USD 4.5 billion |
| Market Expected CAGR (2023 to 2033) | 19.2% |
Explore Life Science & Biotechnology Insights
View Reports
Competent Cells Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
